Tiger’s Take: S+N Joins the "GLP-1 Denial" narrative. Their Q3 guidance cut and failed DePuy Synthes merger talks mask a critical issue: U.S. Knees dropped 7.3%. S+N blames soft markets and frames GLP-1s as a future "funnel expander," but patient realities contradict this.
When Smith+Nephew dropped its Q3 2026 trading update, it brought a double dose of market-shaking news: a cut to full-year guidance, and the revelation that leadership quietly approached J&J earlier this year about combining with DePuy Synthes before talks ultimately fizzled out.
While the aborted J&J courtship grabbed the financial headlines, the real operational story lies hidden in the geographic splits. S+N reported 3.4% overall underlying revenue growth, heavily propped up by a stellar +11.2% surge in Sports Medicine Joint Repair. But look under the hood at the U.S. reconstructive business, and you see a glaring red stain: U.S. Knees plummeted 7.3%, and U.S. Hips slipped 1.0%.
Much like Stryker’s playbook the week prior, S+N management is pointing toward broader "soft market conditions" and regional execution bumps. And looking closely at executive commentary across the MedTech landscape, S+N leader...
